In the British Journal of Cancer this week, researchers in the UK report that NT5E is epigenetically regulated in patients with malignant melanoma. The team analyzed the expression and regulation of NT5E in malignant melanoma cell lines, and in samples of primary and metastatic melanomas, and found that the gene is subject to epigenetic regulation in the disease. It is down-regulated by methylation-dependent transcriptional silencing in several cell lines, the team writes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.